The primary outcome , recurrent symptomatic , objectively confirmed VTE and related deaths during @ months of treatment occurred in @ of the @ dabigatran patients ( @ % ) compared with @ of the @ warfarin patients ( @ % ; hazard ratio , @ ; @ % confidence interval -LSB- CI -RSB- , @-@ @ ; absolute risk difference , @ % ; @ % CI , -@ to @ ; P < @ for the prespecified noninferiority margin for both criteria ) .